Want to see HK:0950 full AI Analyst Report?
Top Page
Lee's Pharmaceutical Holdings Limited
(0950)
Select Model
Select Model
Rating:68Neutral
Price Target:
HK$1.00
▼(-35.48% Downside)
Action:Reiterated
Date:09/17/26
The score is driven primarily by very strong valuation (low P/E and solid dividend yield) and a generally improving financial profile (strong TTM revenue growth, improving net margin, and low leverage). These positives are tempered by weaker technical signals (price below key short-term averages and muted momentum) and lingering concerns about operating-profit and cash-flow consistency.
Positive Factors
Strong Revenue Growth
TTM revenue growth of approximately 30% indicates strong recent demand and expanding commercial activity across the company’s pharmaceutical portfolio. Sustained top-line momentum can support greater operating scale, product investment, regulatory activities, and broader market penetration over the next several quarters.
Negative Factors
Weak Operating Profit
Weak TTM EBIT compared with prior annual periods raises concern about the durability of operating earnings despite strong revenue growth. Profit volatility makes future performance harder to underwrite and suggests that product mix, operating costs, or commercialization economics may not yet be consistently favorable.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
TTM revenue growth of approximately 30% indicates strong recent demand and expanding commercial activity across the company’s pharmaceutical portfolio. Sustained top-line momentum can support greater operating scale, product investment, regulatory activities, and broader market penetration over the next several quarters.
Read all positive factors
Lee's Pharmaceutical Holdings Limited (0950) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$688.94M
Dividend Yield5%
Average Volume (3M)789.60K
Price to Earnings (P/E)4.1
Beta (1Y)0.85
Revenue Growth7.05%
EPS Growth22.46%
CountryHK
Employees1,094
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.28
Shares Outstanding588,835,300
10 Day Avg. Volume289,350
30 Day Avg. Volume789,600
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.44
Price to Sales (P/S)0.62
P/FCF Ratio8.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lee's Pharmaceutical Holdings Limited Business Overview & Revenue Model
Company Description
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such a...
How the Company Makes Money
The company primarily makes money by commercializing pharmaceutical products and related rights across its operating markets. Key revenue streams typically include: (1) Product sales: revenue from selling prescription medicines (including specialt...
Lee's Pharmaceutical Holdings Limited Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
74
Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.94B | 1.44B | 1.40B | 1.05B | 1.23B | 1.27B |
| Gross Profit | 1.04B | 729.56M | 753.36M | 551.31M | 770.75M | 806.28M |
| EBITDA | 173.82M | 198.04M | 260.87M | 193.05M | 229.06M | 2.13B |
| Net Income | 167.27M | 91.94M | 93.10M | 16.70M | 51.28M | 1.99B |
Balance Sheet | ||||||
| Total Assets | 3.48B | 3.46B | 2.62B | 2.89B | 2.78B | 3.64B |
| Cash, Cash Equivalents and Short-Term Investments | 364.39M | 349.90M | 216.84M | 171.00M | 189.30M | 277.53M |
| Total Debt | 249.84M | 310.27M | 227.30M | 204.14M | 163.49M | 267.14M |
| Total Liabilities | 1.54B | 1.56B | 1.07B | 930.07M | 939.50M | 1.25B |
| Stockholders Equity | 2.13B | 2.05B | 1.65B | 2.04B | 1.92B | 2.46B |
Cash Flow | ||||||
| Free Cash Flow | 413.26M | 101.35M | 34.45M | -49.63M | 69.81M | -160.04M |
| Operating Cash Flow | 577.42M | 332.90M | 242.01M | 110.08M | 283.63M | 210.68M |
| Investing Cash Flow | -446.91M | -235.76M | -190.23M | -145.22M | -256.05M | -370.28M |
| Financing Cash Flow | -52.26M | 35.58M | -1.96M | 13.44M | -128.60M | 60.97M |
Lee's Pharmaceutical Holdings Limited Technical Analysis
Neutral
1.55
Price Trends
1.13
Positive
1.09
Positive
1.22
Negative
Market Momentum
<0.01
Positive
49.78
Neutral
26.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0950, the sentiment is Neutral. The current price of 1.55 is above the 20-day moving average (MA) of 1.16, above the 50-day MA of 1.13, and above the 200-day MA of 1.22, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 49.78 is Neutral, neither overbought nor oversold. The STOCH value of 26.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0950.
Lee's Pharmaceutical Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$763.52M | 7.66 | 13.59% | 7.55% | 10.63% | 39.44% | |
77 Outperform | HK$1.82B | 6.36 | 13.26% | 9.42% | -0.47% | -0.40% | |
68 Neutral | HK$688.94M | 4.09 | 8.02% | 5.00% | 7.05% | 22.46% | |
53 Neutral | HK$417.89M | 91.67 | 0.34% | 84.69% | -8.30% | -44.44% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$680.08M | -246.83 | -0.66% | 1.15% | 18.14% | 98.32% | |
43 Neutral | HK$136.41M | -4.31 | -21.73% | 0.48% | -6.71% | 43.14% |
* Healthcare Sector Average
HK:0950
Lee's Pharmaceutical Holdings Limited
1.16
-1.02
-46.92%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.35
-0.12
-25.53%
HK:1498
PuraPharm Corp. Ltd.
0.25
-0.20
-44.32%
HK:1652
Fusen Pharmaceutical Co., Ltd.
0.93
0.09
10.12%
HK:0239
Pak Fah Yeow International Limited
2.44
0.23
10.41%
HK:2633
Jacobson Pharma Corporation Limited
0.96
-0.37
-27.87%
Lee's Pharmaceutical Holdings Limited Corporate Events
Lee’s Pharm licenses next-generation PARP1 cancer drug OC-3 for Greater China and Southeast Asia
Sep 9, 2026
Lee’s Pharmaceutical has strengthened its oncology portfolio by securing exclusive rights from U.S. biotech 1cBio to develop, manufacture and commercialise OC-3, a next-generation PARP1-selective inhibitor, across Mainland China, Hong Kong, ...
Lee’s Pharmaceutical Delivers Strong Interim Profit Growth on Higher-Margin Drug Mix
Aug 31, 2026
Lee’s Pharmaceutical reported a solid set of interim results for the six months ended 30 June 2026, with revenue rising 14.6% year-on-year to HK$796.6 million and profit attributable to shareholders surging 41.4% to HK$95.0 million. Earnings...
Lee’s Pharmaceutical Declares Interim Cash Dividend for First Half of 2026
Aug 31, 2026
Lee’s Pharmaceutical Holdings Limited has declared an interim ordinary cash dividend of HKD 0.035 per share for the six months ended 30 June 2026, covering the financial year ending 31 December 2026. The move underscores the company’s ...
Lee’s Pharmaceutical forecasts higher interim profit on stronger margins and product mix
Aug 26, 2026
Lee’s Pharmaceutical Holdings Limited expects to report an unaudited net profit attributable to shareholders of HK$85 million to HK$95 million for the six months ended 30 June 2026, up from HK$67.2 million a year earlier. The interim results...
Lee’s Pharmaceutical Sets Board Meeting to Review 2026 Interim Results and Dividend
Aug 18, 2026
Lee’s Pharmaceutical Holdings Limited has scheduled a board meeting for 31 August 2026 in Hong Kong to review and approve the group’s unaudited interim results for the six months ended 30 June 2026. The board will also consider whether...
Lee’s Pharm Wins NMPA Nod to Trial First In-House ADC ZK2401
Jul 30, 2026
Lee’s Pharmaceutical has secured acceptance from China’s National Medical Products Administration for an Investigational New Drug application for ZK2401, a proprietary antibody-drug conjugate built on its approved anti-PD-L1 antibody S...
Lee’s Pharm Licenses Interferon Alpha-2b to Ashlins for Markets Outside Greater China
Jul 17, 2026
Lee’s Pharmaceutical Holdings Limited has signed an exclusive license-out and supply agreement with Ashlins Ocular Pharmaceuticals, a U.S.-based biopharmaceutical company, for Interferon Alpha-2b products in all markets outside Mainland Chin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.